Greater fear of hypoglycaemia with premixed insulin than with basal-bolus insulin glargine and glulisine: patient-reported outcomes from a 60-week randomised study

Premixed Insulin ◽

Randomised Study ◽

Patient Reported ◽

Bolus Insulin ◽

2327-PUB: Real-World Patient-Reported Outcomes (PROs) with Insulin Glargine 300 U/ml (Gla-300) in Basal Bolus-Treated People with Type 2 Diabetes (T2DM): The MAGE Study

Diabetes ◽

10.2337/db19-2327-pub ◽

2019 ◽

Vol 68 (Supplement 1) ◽

pp. 2327-PUB ◽

Cited By ~ 1

Author(s):

ANN A. VERHAEGEN ◽

ANDRÉ SCHEEN ◽

KATHY C. ALEXANDRE ◽

JACQUES BRUHWYLER ◽

IDES M. COLIN

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Real World ◽

Patient Reported ◽

SWITCHING FROM PREMIXED INSULIN TO BASAL–BOLUS INSULIN GLARGINE PLUS RAPID-ACTING INSULIN: THE ATLANTIC STUDY

Acta Clinica Belgica ◽

10.2143/acb.68.1.2062716 ◽

2013 ◽

Vol 68 (1) ◽

pp. 28-33 ◽

Cited By ~ 14

Author(s):

C Mathieu ◽

F Storms ◽

J Tits ◽

TF Veneman ◽

IM Colin

Keyword(s):

Insulin Glargine ◽

Premixed Insulin ◽

Acting Insulin ◽

Bolus Insulin ◽

Review for "IDegLira improves patient reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal–bolus therapy"

10.1111/dom.13851/v1/review1 ◽

2019 ◽

Keyword(s):

Patient Reported ◽

Decision letter for "IDegLira improves patient reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal–bolus therapy"

10.1111/dom.13851/v1/decision1 ◽

2019 ◽

Keyword(s):

Patient Reported ◽

Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial

The Lancet Diabetes & Endocrinology ◽

10.1016/s2213-8587(15)00041-8 ◽

2015 ◽

Vol 3 (4) ◽

pp. 254-262 ◽

Cited By ~ 23

Author(s):

Weiping Jia ◽

Xinhua Xiao ◽

Qiuhe Ji ◽

Kyu-Jeung Ahn ◽

Lee-Ming Chuang ◽

...

Keyword(s):

Insulin Lispro ◽

Controlled Trial ◽

Premixed Insulin ◽

Open Label ◽

Once Daily ◽

Asian Patients ◽

Bolus Insulin ◽

Randomised Controlled ◽

Patient-Reported Outcomes in Patients with T2D and increased CV risk on Tirzepatide or Insulin Glargine (SURPASS-4)

10.26226/morressier.6179df327c09fc044a974479 ◽

2021 ◽

Author(s):

Kristina Secnik Boye ◽

Imre Pavo ◽

Russell J. Wiese ◽

Zhengyu Yang ◽

Govinda J. Weerakkody ◽

...

Keyword(s):

Insulin Glargine ◽

Patient Reported

Review for "IDegLira improves patient reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal–bolus therapy"

10.1111/dom.13851/v2/review1 ◽

2019 ◽

Keyword(s):

Patient Reported ◽

Decision letter for "IDegLira improves patient reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal–bolus therapy"

10.1111/dom.13851/v2/decision1 ◽

2019 ◽

Keyword(s):

Patient Reported ◽

Patient-Reported Outcomes with Insulin Glargine 300 U/mL in People with Type 2 Diabetes: The MAGE Multicenter Observational Study

Diabetes Therapy ◽

10.1007/s13300-020-00866-2 ◽

2020 ◽

Vol 11 (8) ◽

pp. 1835-1847

Author(s):

Ides M. Colin ◽

Kathy Alexandre ◽

Jacques Bruhwyler ◽

André Scheen ◽

Ann Verhaegen

Keyword(s):

Type 2 Diabetes ◽

Observational Study ◽

Insulin Glargine ◽

Multicenter Observational Study ◽

Patient Reported

Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma

European Journal of Cancer ◽

10.1016/j.ejca.2017.08.032 ◽

2017 ◽

Vol 86 ◽

pp. 115-124 ◽

Cited By ~ 42

Author(s):

Teresa M. Petrella ◽

Caroline Robert ◽

Erika Richtig ◽

Wilson H. Miller ◽

Giuseppe V. Masucci ◽

...

Keyword(s):

Advanced Melanoma ◽

Randomised Study ◽

Patient Reported